youtube_live
Q3 2026 earnings • in 5 days
See detailschevron_right
EDIT:NASDAQ
Editas Medicine Inc
$2.93
arrow_downward
-0.68%(-0.020) 1D
$2.88
arrow_downward
-1.71% (-0.050)bedtimeAfter hours
Closed: Oct 29, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
$2.94
High
$2.98
Low
$2.86
Mkt. cap
449.99M
Avg. vol.
2.98M
Volume
3.23M
52-wk high
$3.94
52-wk low
$1.66
EPS
-$0.74
Beta
2.00
Shares outstanding
153.58M
No. of employees
87
Open
$2.94
High
$2.98
Low
$2.86
Mkt. cap
449.99M
Avg. vol.
2.98M
Volume
3.23M
52-wk high
$3.94
52-wk low
$1.66
EPS
-$0.74
Beta
2.00
Shares outstanding
153.58M
No. of employees
87
News stories
From web sources and news partners
Yahoo Finance
·
1 hour ago
Bitcoin Is Beating the S&P 500, so Why Is $85,000 Still Out of Reach?
www.tokenpost.com
·
45 minutes ago
ServiceNow Tumbles 26.95% as AI-Linked Stocks Fall at U.S. Close
ChartMill
·
3 hours ago
After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fall
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc
Analyst ratings
Based on 8 analysts giving stock ratings to EDIT in the past 3 months
Buy
Buy
6
Hold
1
Sell
1
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for EDIT in the last 3 months.
Highest
Current $2.93
$8.00 (+173.04%)
Average
$5.67 (+93.52%)
Lowest
$4.00 (+36.52%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Yanan Zhu Wells Fargo | Buy | Upgraded | $6.00 | +104.8% | 10/08/2026 |
Debjit Chattopadhyay Guggenheim | Buy | Upgraded | $5.00 | +70.6% | 09/23/2026 |
Rick Bienkowski Ladenburg Thalmann & Co. | Buy | Initiated | $6.00 | +104.8% | 08/18/2026 |
Alec Stranahan Bank of America Securities | Sell | Reiterated | - | - | 08/07/2026 |
Luca Issi RBC Capital | Hold | Maintained | $4.00 | +36.5% | 08/05/2026 |
Mitchell Kapoor H.C. Wainwright | Buy | Reiterated | $5.00 | +70.6% | 08/06/2026 |
Phil Nadeau TD Cowen | Buy | Maintained | - | - | 08/05/2026 |
Boris Peaker JonesTrading | Buy | Maintained | $8.00 | +173% | 08/05/2026 |
Jonathan Miller Evercore ISI | Buy | Maintained | $15.00 | +411.9% | 05/27/2026 |
Geulah Livshits Chardan Capital | Buy | Reiterated | $4.00 | +36.5% | 05/05/2026 |
Soumit Roy JonesTrading | Buy | Maintained | $8.00 | +173% | 04/06/2026 |
Joon Lee Truist Financial | Hold | Maintained | - | - | 03/17/2026 |
Brian Cheng J.P. Morgan | Sell | Maintained | - | - | 03/13/2026 |
William Maughan Clear Street | Buy | Maintained | $4.60 | +57% | 03/10/2026 |
Next call in 5 days
Tue, Nov 3, 11:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.21
Revenue / Est. (USD)
- / 4.53M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 7.54M | 24.74M | 2.83M | 11.89M |
Cost of goods sold | 19.78M | 27.40M | 17.60M | 20.18M |
Cost of revenue | 19.78M | 27.40M | 17.60M | 20.18M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 12.32M | 11.35M | 10.23M | 11.60M |
Operating expense | 12.32M | 11.35M | 10.23M | 11.60M |
Total operating expenses | 32.09M | 38.76M | 27.83M | 31.78M |
Operating income | -24.55M | -14.02M | -25.00M | -19.89M |
Other non operating income | -1.00K | 2.18M | -113.00K | 17.00K |
EBT including unusual items | -25.12M | -5.62M | -24.98M | -18.23M |
EBT excluding unusual items | -25.12M | -9.69M | -24.98M | -19.57M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -25.12M | -5.62M | -24.98M | -18.23M |
Net profit margin | -332.98% | -22.72% | -882.44% | -153.32% |
Earnings per share | -0.28 | -0.06 | -0.26 | -0.15 |
Interest and investment income | 1.83M | 2.14M | 1.21M | 1.37M |
Interest expense | -2.40M | - | -1.07M | -1.06M |
Net interest expenses | -568.00K | 2.14M | 134.00K | 307.00K |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -23.83M | -13.21M | -24.52M | -19.48M |
Gain or loss from assets sale | - | 34.00K | - | 111.00K |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events